introduction
Treatment options for advanced gastric cancer (AGC) are increasing. Drugs such as oxaliplatin, irinotecan and docetaxel have been evaluated by phase II and III clinical trials during the last years and showed substantial efficacy [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . Nevertheless, prognosis for the majority of patients with AGC remains poor and 2-year survival rates rarely exceed 20%. Therefore, avoiding treatment-associated toxicity, which may limit the quality of live, represents a major objective.
Particularly, the combination of docetaxel, cisplatin and fluorouracil (DCF) improved several efficacy parameters in AGC, but was associated with substantial toxicity, including grade 3/4 neutropenia and complicated neutropenia in 82% and 29% of patients, respectively [7] . The combination of docetaxel with the less toxic back bone regimen 5-fluorouracil, leucovorin and oxaliplatin (FLO) [1, 2] within a recent phase II study showed improved tolerability as compared with DCF, but grade 3/4 neutropenia was still observed in 48% of patients [11] . The purpose of our study was to search for pharmacogenetic markers that might identify patients with an increased risk to encounter high-grade hematotoxicity in this study.
We have investigated the impact of 24 polymorphisms within 15 genes that are involved in transport and metabolism of the applied drugs within the 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) regimen, in DNA repair or in folate metabolism on appearance of hematotoxicity in patients with AGC with FLOT treatment. Selected genes were thymidylate synthase (TS); methylenetetrahydrofolate reductaxe (MTHFR); orotate phosphoribosyltransferase (OPRT); methionine synthase (MTR); glutathione S-tranferases (GSTP1, GSTT1, GSTM1); xeroderma pigmentosum group D (XPD); X-ray repair cross complementing group 1 (XRCC1); xeroderma pigmentosum group A (XPA); excision repair cross complementing-group 1 (ERCC1); ATP-binding cassette, subfamily B member 1 (ABCB1); ATP-binding cassette, subfamily G member 2 (ABCG2) and cytochrome P450 3A4 (Cyp 3A4) and Cyp 3A5.
patients and methods

study population
In all, 59 patients were enrolled in a phase II study evaluating the safety and efficacy of a biweekly chemotherapy regimen containing oxaliplatin 85 mg/m 2 , leucovorin 200 mg/m 2 and docetaxel 50 mg/m 2 , each as a 1-to 2-h i.v. infusion followed by 5-fluorouracil (FU) 2600 mg/m 2 as a 24-h continuous infusion (FLOT) [11] . Hematotoxicity was monitored prior each chemotherapy administration and included the evaluation of anemia, leukopenia, neutropenia and thrombocytopenia according to the National Cancer Institute-Common Toxicity Criteria (version 2.0). Prophylactic granulocyte colony-stimulating factor (G-CSF) was not administered. Blood samples for genotyping were collected prospectively and were available from 50 patients. All participating patients provided a signed informed consent for genetic testing and the study including its translational part was approved by the local ethics committee.
DNA extraction and genotyping
DNA was extracted from whole blood using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) without modifications. Genotypes of TS (TS 28-bp repeat polymorphism, G/C SNP within the second repeat of the 3R variant and TS1394del6), MTHFR (C677T, A1298C), MTR-A2756G, ERCC1 (C118T, C8092A), XPD (Asp312Asn, Lys751Gln), XRCC1-Arg399Gln, XPA-A23G, Cyp3A4*1B, GSTP1-Ile105Val and null-genotypes of GSTM1 and GSTT1 were determined as described elsewhere [12] [13] [14] [15] [16] .
We have designed a PCR-based restriction fragment length polymorphism technique for genotyping the ABCB1-G2677T (G2677A) polymorphism. Primers used were 5#-TGCAATAGCAGGAGTTGTTGA-3# and 5#-AAAAGATTGCTTTGAGGAATGG-3#. PCR was carried out as follows: 95°C for 10 min followed by 35 cycles of 95°C for 20 s, 58°C for 1 min and 72°C for 20 s followed by a final elongation step (72°C for 5 s). The PCR product was then digested by BseY I to discriminate between G>T (GG = 134, 74 bp; GT = 211, 137, 74 bp; TT = 211 bp) and in a second assay with Bsr I to discriminate between G>A (GG = 211 bp; GA = 132, 79 bp; AA = 211, 132, 79 bp). Samples were genotyped for OPRT-Gly213Ala, ABCB11-C1236T, ABCB11-C3435T, ABCG2-C421A, Cyp3A4*3, Cyp3A5*2 and Cyp3A5*3C polymorphisms using a custom-designed Assay-onDemand (OPRT-Gly213Ala: C_1901477_10,rs1801019; ABCB1-C1236T: C_7586662_10,rs1128503; ABCB11 C3435T: C_7586657_20,rs1045642; ABCG2-C421A: C_15854163_70,rs2231142; Cyp3A4*3: C_27535825_20,rs4986910; Cyp3A5*2: C_30633862_10,rs28365083; Cyp3A5*3C: C_26201809_30,rs776746) from Applied Biosystems (Darmstadt, Germany 
patients' characteristics
Patients' demographic and tumor-related information are provided in Table 1 . Hematotoxicity grade 3/4 including anemia, leukopenia, neutropenia and thrombocytopenia was observed in 24 of 50 eligible patients (48%). Neutropenia grade 3/4 was the most observed grade 3/4 hematotoxicity with a frequency of 42% (n = 21) followed by grade 3/4 leucopenia with 24% (n = 12). Grade 3/4 anemia occurred only in two patients (4%) and grade 3/4 thrombocytopenia in only one patient (2%). Detection of genetic polymorphisms was successful in all patients. All analyzed single-nucleotide polymorphisms (SNP) showed no deviation from the HWE.
TS polymorphisms and hematotoxicity
We observed a significant association between TS promoter polymorphisms and hematotoxicity. TS promoter polymorphisms were divided into a low-expressing group A (2R/2R, 2R/3RC, 3RC/3RC) and a high-expressing group B (2R/3RG, 3RC/3RG, 3RG/3RG) according to the literature [17, 18] . Patients possessing one of the group A genotypes were at significantly increased risk for grade 3/4 hematotoxicity compared with patients harboring a TS-group B genotype ( Table 2 ). In all, 59% (20 of 34) of patients with TS-group A genotypes developed grade 3/4 hematotoxicity compared with only 25% (4 of 16) of patients with TS-group B genotypes (P = 0.035, Fisher's exact test, two sided) ( Figure 1 ). In fact, 83% of patients with grade 3 or 4 toxicity harbored a TS-group A genotype. Furthermore, TS-group A genotypes were identified as the sole independent risk factor for grade 3/4 overall hematotoxicity [hazard ratio 4.62 (95% confidence interval 1.22; 17.44), P = 0.024] using a stepwise multivariate logistic regression model. The association between TS promoter polymorphisms and hematotoxicity was most significant for neutropenia with 53% (18 of 34) of TS-group A patients showing grade 3/4 neutropenia compared with only 19% (3 of 16) of TS-group B patients (P = 0.032, Fisher's exact test) (Figure 2 ). In fact, 86% of patients with grade 3 or 4 neutropenia harbored a TS-group A genotype. The association between TS-group A genotypes and increased risk for grade 3/4 neutropenia could be confirmed by stepwise multivariate logistic regression analyses (Table 3 ). In addition, increasing numbers of administered treatment cycles could be determined as an independent risk 
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factor for developing grade 3/4 neutropenia ( Table 3) . None of the other analyzed polymorphisms was found to have significant impact on hematotoxicity in this study population.
discussion
Here, we demonstrated for the first time an association between TS promoter polymorphisms and hematotoxicity in AGC patients treated with a docetaxel-based triplet chemotherapy regimen. Patients with a TS-group A genotype were likely to develop grade 3/4 neutropenia. Nearly 90% of observed grade 3/4 neutropenia in this study could be attributed to patients harboring group A genotypes. Reduced TS expression has been shown to be associated with enhanced 5-fluorouracil (5-FU) activity [19, 20] and these group A genotypes have been shown to be associated with decreased TS expression [17, 18] . However, in vivo data that are linking TS promoter polymorphisms to 5-FU-induced toxicity are rare [21, 22] and in case of AGC even lacking. The TS promoter contains a double polymorphism that is characterized by a 28-bp repeat with mainly two or three repeat (2R, 3R) with a G>C SNP within the second repeat of the 3R variant [17, 18] . In general, the 2R variant could be linked to decreased TS expression and the 3R variant to increased TS expression [17, 18, 22, 23] . The described G>C SNP is supposed to reduce the expression level of the 3R variant to that of the 2R variant [17, 18] . The reports by Pullarkat et al. and Lecomte et al. both describe an association between the 2R/2R genotype and enhanced 5-FU-derived high-grade toxicity [21, 22] . However, these reports did not include the G>C SNP in their analyses. In our present study, there was also a trend for more grade 3/4 hematotoxicity in patients with the 2R/2R or 2R/3R genotype compared with patients harboring the 3R/3R genotype (data not shown). Neutropenia grade 3/4 occurred in 66.7%, 38.5% and 25% of 2R/2R, 2R/3R and 3R/3R carriers, respectively (P = 0.10, chi-square test). We also carried out haplotype-based analyses including the TS promoter polymorphisms and the TS1394del6 within the 3#-untranslated region (UTR) of the gene. Thus, haplotype analyses did not reveal additional significant information (data not shown). In addition, we could not identify a significant association between TS promoter genotypes or occurrence of high grade hematotoxicity and treatment efficacy in terms of overall response, progressionfree and overall survival in this study (data not shown).
There are three possible explanations for the observed association between TS promoter genotypes and the occurrence of grade 3/4 hematotoxicity. The first and obvious one is the mentioned association between reduced TS expression and enhanced 5-FU activity. TS, as the sole de novo source of thymidylate, is the target of 5-FU. The lower the TS expression level the more 5-FU activity can be expected. Second, TS plays an important role in various folate-dependent pathways such as purine synthesis, methionine regeneration or DNA methylation [24] . In conclusion, TS represents an important enzyme in proliferating or regenerating cells, including those of the hematopoietic system. An impaired TS function due to reduced TS expression, therefore, may lead to impaired regeneration after chemotherapy-induced bone marrow depression caused by highly immunosuppressive agents such as docetaxel. This suggestion provides a possible explanation of the observed association of TS-group A genotypes with grade 3/4 neutropenia in this study since neutropenia is a consequence of toxic injury of proliferating myeloid precursor cells in the bone marrow. To date, in vitro or in vivo data proving this hypothesis are lacking. In addition, a highly synergistic effect of docetaxel and 5-FU has been shown [25] . Within this synergy between taxanes and fluoropyrimidines, TS expression seems to play an important role [26] . In preclinical studies, exposure of gastric and colon cancer cell lines to taxanes have led to changes in TS expression [27, 28] suggesting a direct role of TS also in taxane activity. These observations may provide an additional mechanism that might underlie the observed predictive value of TS promoter polymorphisms on hematotoxicity in our study.
In this study, a triple combination regimen consisting of FLOT has been used. FLOT results from the addition of docetaxel at 50 mg/m 2 every 2 weeks to the doublet regimen FLO [1, 2] . Within the limitations of a cross-study comparison, the addition of docetaxel to the FLO regimen has raised the observed hematotoxicity from 11.8% [2] to 48% [11] . Due to the increased rate of grade 3/4 neutropenia with the FLOT regimen compared with the FLO regimen, special focus was set on pharmacogenetics of docetaxel. Therefore, polymorphisms of Cyp 3A4, Cyp 3A5, ABCB1 and ABCG2 have been analyzed. However, none of these polymorphisms turned out to have an impact on hematotoxicity in this translational study. These findings are in agreement with a study by Marsh et al. [29] investigating these and other polymorphisms in a large cohort of ovarian cancer patients with taxane plus platinum-based chemotherapy regimens. The authors did not identify any clear pharmacogenetic marker for toxicity prediction in their study. We have also analyzed polymorphisms of genes being involved in metabolism of platinum compounds and in DNA repair (GSTP1, GSTT1, GSTM1, XPD, XPA, ERCC1, XRCC1). Again we did not find an association between these polymorphisms original article Annals of Oncology and hematotoxicity in our study which also is in line with the study by Marsh et al. [29] . Grade 3/4 neutropenia is the main source of infectious or febrile complication during chemotherapy treatment of patients. Two patients suffered from complicated neutropenia (both with TS-group A promoter genotypes) in this study. Therefore, if confirmed, AGC patients with a TS-group A promoter genotype should receive an intensified safety monitoring during FLOT therapy and may qualify for prophylactic G-CSF administration.
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